Get started

Stockstowatch

SPY perspectives - two potential scenarios (update)Friday we saw big activity in volumes and the price pushed below the internal support line. With the two cases currently we are taking the path of the bearish one. On Thursday we've closed in a pinbar which was an additional price action confirmation that we are heading into a reversal. If the current conditions remain I would expect for the price to fall down towards the $360 zone. It is a psychological level as well and there will be an attempt to keep that zone unbreached. Technicals are all in faveour of a correction. Fundamentals remain to be worsened, but definetly Wall Street does not like the trading of WSB's participants and that gives a negative tick to the market.
AMEX:SPYShort
by DailyChartist
SIEB Soars as Reddit Feed Targets Another Short SqueezeBrokerage Firm Siebert Soars as Reddit Feed Targets Another Short Squeeze SIEB spiked Friday after the brokerage firm became the latest stock to attract the attention of ordinary investors prompted by a Reddit message board called WallStreetBets. Siebert, which does retail brokerage business through its Muriel Siebert subsidiary, said that it has not released any news on Friday, Dow Jones reported. WallStreetBets has been trying to collectively push shares of these companies higher in a bid to force hedge funds and other large investors to abandon their short positions -- bets that stock prices will decline -- in those companies. www.thestreet.com
NASDAQ:SIEB
by AlenCiken
2
About to take flight?I have been waiting for some of the most unloved parts of the market to pick up and that includes RTX and Aerospace. A decent reversal might be setting up if todays price action is any indication of what could come in the future. Stock is still well below highs in June and I think the outlook is better now then it was then. If we can hold this support zone and break above the trendlines the stock could be heading higher toward 76. Below 64 means the play is invalid. Not investment advice
NYSE:RTXLong
by IngenuityTrading
2
Reddit army buying heavily shorted REV stockShares of REV were jumping again as a massive short squeeze on consumer stocks continued into its third day. The squeeze instigated by a group of traders on Gamestop has now spread to other heavily shorted stocks There was no news out on any of these three stocks today, and certainly nothing of the kind that would generate this kind of movement for fundamental reasons. Instead, traders on platforms like Reddit have figured out that they can take advantage of heavily shorted small-cap stocks if enough of them start buying them, and that's what's happened with REV stock. When a stock is shorted and starts to go up, short-sellers eventually have to buy back the shares or risk further losses, including a margin call forcing the repurchase. At Revlon, 31% of the stock's float was sold short as of the end of December. www.fool.com
R
by AlenCiken
A massive short squeeze on PETSShares of PETS were jumping again as a massive short squeeze on consumer stocks continued into its third day. The squeeze instigated by a group of traders on Gamestop has now spread to other heavily shorted stocks, There was no news out on any of these three stocks today, and certainly nothing of the kind that would generate this kind of movement for fundamental reasons. Instead, traders on platforms like Reddit have figured out that they can take advantage of heavily shorted small-cap stocks if enough of them start buying them, and that's what's happened with all three of these stocks. When a stock is shorted and starts to go up, short-sellers eventually have to buy back the shares or risk further losses, including a margin call forcing the repurchase. Though only about 15% of the float is sold short, traders were aggressive to pump up the stock as daily trading volume rose as high as 358 million shares on Monday, up from around 3 million normally. As of midday today, volume had already topped 200 million. PetMed Express, an online pet pharmacy, entered the new year with 41% of it stock sold short. www.fool.com
NASDAQ:PETS
by AlenCiken
Why GSX stock soared? Short-sellers are getting squeezed.......The coronavirus is getting worse in China, and it's possible that investors believe that's a good thing for GSX. GSX is a remote-education company in China, and its business grew substantially in 2020. And if COVID-19 gets worse in that country, it's possible 2021 will be another good year for this business. According to The Associated Press, new coronavirus cases are causing the Chinese government to lock down two hospitals in Shanghai. it appears investors might expect GSX Techedu's services will be in greater demand if the pandemic worsens in China. This is further complicated by short interest in this stock. According to Yahoo! Finance, around half of the stock's float was sold short up until recently. If investors are buying shares over the last few days because of the news coming out of China, it could be causing a short squeeze, as short-sellers are forced to cover their bearish positions. Over 22% of GSX stock is sold short, giving it a short interest ratio of almost 14 days (anything over seven days is considered a lot). While that indicates short-sellers are getting squeezed, or being forced to cover their positions at ever-higher prices, it's more just a phenomenon flooding the market at the moment. the company is under fire from many popular short-sellers, who claim GSX Techedu is a fraud. And the company has indeed admitted that it is under investigation from the Securities and Exchange Commission (SEC). While that investigation is ongoing and it may turn out that everything is above board, this has caused a lot of people to actively bet against this stock. The company faces the possibility of being delisted from major U.S. exchanges if the SEC finds wrongdoing. Therefore, it's important to approach a GSX Techedu investment fully aware of this risk. Investors shouldn't be swayed by these price swings, and investors would be smart to sit on the sidelines until GSX Techedu sorts out the battle taking place between short-sellers and those long on its stock. www.fool.com
G
by AlenCiken
Overstock to be limited partner in blockchain fundOverstock Partners with Pelion Venture Partners to Oversee Medici Ventures’ Blockchain Assets Overstock to be limited partner in blockchain fund OSTK today announces it will be converting Medici Ventures, Inc., its wholly owned blockchain-focused subsidiary, to a limited partnership (the “Fund”). An entity within Pelion Venture Partners, a third-party venture capital firm with a proven track record of successfully investing in early stage companies, will act as the general partner of the Fund. Pelion has blockchain and technology expertise with early stage companies and has helped guide many companies to economic success. Under the arrangement, which will close after obtaining necessary legal and regulatory approvals, Medici Ventures will be converted into a limited partnership. finance.yahoo.com
O
by AlenCiken
CVLB Expects 2020 Revenue up 205% to Record $38.0 MillionConversion Labs Expects 2020 Revenue up 205% to Record $38.0 Million, Subscription ARR up 525% to $26.0 Million preliminary unaudited results for its fourth quarter and full year ended December 31, 2020. Revenue for the fourth quarter is expected to total $13.6 million, up 265% from $3.7 million in the fourth quarter of 2019. Revenue for the full year is expected to total $38.0 million, up 205% from $12.5 million in 2019. We ended the year exceptionally strong, with December revenues hitting a monthly record of $5.1 million, up 321% over December of last year. In fact, December 2020 alone eclipsed the whole of the fourth quarter of 2019.” ual recurring revenue (ARR) generated by subscriptions reached $26.0 million by the end of the year, up 525% compared to the end of 2019 (see description of ARR, below). ARR increased by more than $3.0 million from November to December—another record-setting monthly gain. “Given our extensive telehealth platform buildout in 2019, we were prepared when the breakout of the COVID-19 pandemic suddenly accelerated the consumer shift from traditional healthcare to telemedicine,” expect 2021 to be our biggest year yet.” finance.yahoo.com
C
by AlenCiken
3
Equity Investment and Strategic Business CooperationBaozun and iClick Announce Equity Investment and Strategic Business Cooperation As a result of the agreement, Baozun will own 4% of iClick's shares outstanding and control 10% of its voting power. The companies said they entered into a "strategic cooperation framework agreement" and will collaborate on a closed-loop e-commerce service model, focusing on areas like digital marketing, customer service, and fulfillment. That complements Baozun's core business of providing e-commerce services such as marketing, fulfillment, and IT for multinational companies like Microsoft and Nike. Also key in the deal is that both companies will develop a private domain traffic platform for Tencent, the tech giant and owner of the super-app WeChat. A short squeeze may have also helped drive the shares higher. Baozun is subject to a 180-day lock-up period on the above shares subscribed from iClick or purchased from the existing shareholder. finance.yahoo.com
NASDAQ:BZUN
by AlenCiken
Bank of America in risk of a trend reversalMy bearish view for Bank of America is almost confirmed. All is left is a move below $30.59 zone. RSI and MACD are flashing red and point for a continuation of the selling. Volumes are descending as activity is slowing down resent days. Since the bad earnings, the bank is under pressure from investors, but still the downtrend is not entirely confirmed. Given the broader market and perpetual stimulus, BAC may have a second chance to continue its uptrend.
NYSE:BACShort
by DailyChartist
EDSA to Study Investigational Drug as Potential Rescue TheraphyEdesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy EDSA has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients. The sub-study will evaluate the drug as a potential rescue therapy for critically severe COVID-19 cases. This sub-study will allow us to potentially expand the use of EB05 to critically ill patients suffering from profound, medically refractory COVID-19 respiratory failure," Dr. Nijhawan said. finance.yahoo.com
NASDAQ:EDSA
by AlenCiken
Significant and Rapid Reduction in Hepatitis B Surface AntigenInitial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen Data from the first blinded cohort of eight patients, two of whom received placebo and six of whom received a single dose of 6 mg of VIR-3434, showed that six of eight patients achieved a mean reduction of 1.3 log10 IU/mL in serum hepatitis B virus surface antigen (HBsAg) by day eight, the day when nadir was achieved in most patients. Additional data will be submitted for presentation at an upcoming medical conference. A Phase 2 trial combining VIR-3434 with Vir’s HBV-targeting siRNA, VIR-2218, is expected to commence in the second half of this year. finance.yahoo.com
NASDAQ:VIR
by AlenCiken
operating income increase of 527%The company reported revenues of $191.7 million, net income of $10.9 million, and basic EPS (earnings per share) of $6.40. The company also reported operating income of $20.4 million, representing an increase of 527% over the same period last year. During the 2020 fiscal year, the company repurchased 236,908 shares of its common stock at an average price of $7.01 per share. At September 30, 2020, the company reported total assets of $197.2 million and total liabilities of $153.5 million. Stockholders’ equity stood at $43.9 million, or $25.75 per basic common share1. At September 30, 2020, the company had cash and availability under its various lines of credit $37.7 million. The Company completed two significant acquisitions in 2020, Lonesome Oak in January and Precision Marshall in July.
NASDAQ:LIVE
by AlenCiken
1